Levemir Injection, Solution
Product Images NDC 50090-1276

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Levemir (NDC 50090-1276). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

S:\smart\labeling\products\levemir\figures\chemical Structure.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 01)

Chemical structure diagram of Levemir showing the amino acid sequences of two peptide chains labeled A and B. The structure includes disulfide bonds (S-S) connecting cysteine residues and a long fatty acid chain attached to the B29 lysine residue. The diagram illustrates the primary structure of the insulin analog Levemir.*

FDA Label Image

Figure 4a (Aa947266 E27c 432b 8e04 C36168d24ddb 06)

Illustration showing hands removing the cap from a vial, demonstrating part of the preparation process for an injectable medication, consistent with handling steps for Levemir 100 units per mL insulin solution.*

FDA Label Image

Figure 4b (Aa947266 E27c 432b 8e04 C36168d24ddb 07)

An instructional illustration showing a person holding a vial with one hand and using the other hand to remove the cap or cover from the vial. The image is likely part of a series demonstrating preparation steps for Levemir injection.*

FDA Label Image

Figure 6 (Aa947266 E27c 432b 8e04 C36168d24ddb 08)

An instructional illustration showing a hand holding a syringe, with the other hand pulling down a protective cap, indicated by a downward arrow. The image appears to demonstrate a step in the preparation or use of an injectable product.*

FDA Label Image

Figure 7 (Aa947266 E27c 432b 8e04 C36168d24ddb 09)

An instructional illustration showing hands drawing liquid from a vial into a syringe, indicating a step in medication preparation or administration.*

FDA Label Image

Figure 8 (Aa947266 E27c 432b 8e04 C36168d24ddb 10)

An instructional illustration showing hands drawing liquid from a vial into a syringe. The image emphasizes proper needle and syringe positioning, with an arrow pointing downward to indicate direction.*

FDA Label Image

Figure 9 (Aa947266 E27c 432b 8e04 C36168d24ddb 11)

An instructional illustration showing a hand holding a bottle with an injection site at the bottom and a syringe. The image includes arrows indicating the motion of drawing liquid from the bottle into the syringe. This diagram is part of the Levemir 100 units/mL product instructions by A-S Medication Solutions.*

FDA Label Image

Figure 10 (Aa947266 E27c 432b 8e04 C36168d24ddb 12)

Illustration depicting the preparation of a syringe with a vial. One hand holds the vial upside down while the other hand pulls back the plunger to draw liquid into the syringe, demonstrating how to withdraw medication.*

FDA Label Image

Figure 1 (Aa947266 E27c 432b 8e04 C36168d24ddb 13)

An instructional illustration showing a hand holding a syringe with the needle inserted at an angle into the skin of a forearm. A downward arrow indicates the direction of needle insertion.*

FDA Label Image

Step 1 Fig B.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 28)

An instructional illustration showing hands twisting or preparing a part of a pen-like device, likely related to the use or assembly of Levemir insulin delivery. Arrows indicate the direction of twisting or movement to perform the action correctly.*

FDA Label Image

Step 2 Fig C.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 29)

An illustration labeled as Figure C shows a close-up of a hand holding a Levemir insulin pen, focusing on the pen's dosage window and green-colored dial, indicating a step in the injection or dosage-setting process for Levemir 100 IU/mL.*

FDA Label Image

Figure D (Aa947266 E27c 432b 8e04 C36168d24ddb 30)

An instructional illustration showing two panels demonstrating how to twist the NovoFine or NovoFine Plus needle and the NovoTwist needle in the indicated directions, likely for attachment or removal. The image uses hand drawings with arrows to indicate twisting motion to the left.*

FDA Label Image

Figure E (Aa947266 E27c 432b 8e04 C36168d24ddb 31)

An instructional illustration showing the removal of protective caps from the pen needle for NovoFine/NovoFine Plus and NovoTwist. The images highlight how to properly detach each type of cap from the needle before use.*

FDA Label Image

Figure F (Aa947266 E27c 432b 8e04 C36168d24ddb 32)

An instructional illustration showing the use of NovoFine, NovoFine Plus, and NovoTwist needles. The left panel depicts inserting a NovoFine or NovoFine Plus needle into a syringe with a twisting motion. The right panel depicts a similar insertion of a NovoTwist needle by pushing it onto the syringe. The image guides proper needle attachment technique.*

FDA Label Image

Figure G (Aa947266 E27c 432b 8e04 C36168d24ddb 33)

Instructional diagram showing how to connect a syringe to a needle using NovoFine, NovoFine Plus, or NovoTwist needles. It illustrates the steps with arrows indicating the attachment process.*

FDA Label Image

Step 7 Fig H.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 34)

Illustration showing a person adjusting the dose selector on a Levemir insulin pen to 2 units. The image highlights the dose window displaying the number 2 and an arrow indicating the direction to turn the dial for dose selection.*

FDA Label Image

Step 8 Fig I.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 35)

An instructional illustration showing a hand striking or flicking the top of a pen-like insulin delivery device, likely demonstrating a step in preparing the Levemir insulin pen for use, such as removing air bubbles before injection.*

FDA Label Image

Step 9 Fig J.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 36)

Illustration showing a hand holding a Levemir injection pen with an arrow pointing upward. An inset highlights the pen's dial mechanism, indicating a step in the injection preparation or delivery process.*

FDA Label Image

Step 10 Fig K.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 37)

An instructional illustration showing a person adjusting a dosing dial on a Levemir insulin pen, with close-up examples of the dose window displaying 5 units and 24 units selected. The image demonstrates how to select the insulin dose by rotating the dial.*

FDA Label Image

Step 10 Fig L (Aa947266 E27c 432b 8e04 C36168d24ddb 38)

An illustration showing a green and white insulin pen cartridge labeled with blue measurement markings indicating insulin units. The image highlights an approximate amount corresponding to 200 units left in the cartridge. The cartridge is designed for dosing insulin, likely representing the Levemir insulin pen.*

FDA Label Image

Step 11 Fig M (Aa947266 E27c 432b 8e04 C36168d24ddb 39)

An instructional illustration showing front and back views of a human body with shaded areas indicating recommended injection sites for the product Levemir 100 IU/mL. The highlighted injection areas include the abdomen, front and outer thighs, upper outer arms, and the upper buttocks.*

FDA Label Image

Step 12 Fig N.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 40)

An instructional illustration showing a hand holding an injection pen pointing downward with a downward arrow, likely demonstrating a step in administering Levemir insulin injection 100 units/mL.*

FDA Label Image

Step 13 Fig O.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 41)

An instructional illustration showing a hand pressing down on a Levemir injection pen to administer the medication. The image includes a close-up of the dial displaying the dose setting at 0. The illustration guides proper injection technique for Levemir 100 units/mL insulin pen by A-S Medication Solutions.*

FDA Label Image

Step 13 Fig P.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 42)

An instructional illustration showing a hand holding a syringe or pen device filled with medication. A speech bubble above includes the count sequence "1-2-3-4-5-6," indicating to count slowly.*

FDA Label Image

Step 14 Fig Q.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 43)

An instructional illustration showing a syringe with a needle pointing upward above a surface, indicated by an upward arrow. This figure suggests a step in preparing or handling the medication Levemir 100 IU/mL, labeled by A-S Medication Solutions.*

FDA Label Image

Step 15 Fig S.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 45)

An instructional diagram showing the proper assembly of a needle onto a syringe or pen device, depicted with arrows indicating the insertion and alignment process. The image is labeled as Figure S and is related to the administration of Levemir 100 IU/mL insulin.*

FDA Label Image

Step 16 Fig T.jpg (Aa947266 E27c 432b 8e04 C36168d24ddb 46)

An instructional illustration showing two hands holding a device with a green band, with an arrow indicating a twisting or turning motion on the green section. This is likely part of the administration instructions for Levemir 100 IU/mL.*

FDA Label Image

Flextouch Qr Code (Aa947266 E27c 432b 8e04 C36168d24ddb 50)

FDA Label Image

Needle Components. (Image 03)

An instructional diagram showing components of three different NovoFine insulin pen needles: NovoFine, NovoFine Plus, and NovoTwist. Each set displays the outer needle cap, inner needle cap, needle, and paper tab separated in order from left to right.*

FDA Label Image

Figure A Flextouch Pen Components. (Image 04)

An instructional illustration of the Levemir FlexTouch insulin pen showing labeled components, including pen cap, insulin scale, insulin window, dose counter, dose pointer, dose selector, and dose button. The pen is primarily green and blue with the Levemir FlexTouch branding visible.*

FDA Label Image

Step 15 Figure R (Image 05)

An instructional diagram illustrating how to attach the NovoFine Plus needle to the NovoTwist insulin pen. The two-step illustrated sequence shows positioning the needle at an angle and then pushing it straight on to secure it to the pen, emphasizing correct needle attachment technique.*

FDA Label Image

Figure 2: Activity Profiles In Patients With Type 1 Diabetes (Image 06)

A pharmacodynamic graph for Levemir showing glucose infusion rate (mg/kg/min) over 24 hours following insulin injection at doses of 0.2 and 0.4 Units/kg. The chart includes a table comparing pharmacodynamic parameters AUC_GIR and GIR_max for these doses, with higher values at 0.4 U/kg.*

FDA Label Image

Figure 3: Activity Profiles In Patients With Type 2 Diabetes (Image 07)

A pharmacodynamic graph displaying glucose infusion rate (mg/kg/min) over time since insulin injection (hours) for Levemir 100 IU/mL at doses of 0.6 and 1.2 U/kg. The graph includes two lines depicting infusion rates for each dose and a table of pharmacodynamic parameters showing AUC_GIR and GIR_max values for both doses.*

FDA Label Image

Label Image (Lbl500901276)

Levemir Insulin Detemir Injection 100 units/mL label from A-S Medication Solutions. The label includes storage instructions to store at 36 to 46 degrees Fahrenheit, protect from light, and notes that the container holds 10 mL multi-dose vial. It also features a lot number, a QR code, and distributor information for A-S Medication Solutions, Libertyville, IL 60048.*

FDA Label Image

Label Image (Lbl500901475)

Levemir Flextouch Insulin Detemir Injection 100 units/mL label from A-S Medication Solutions. The label details storage instructions, emphasizing protection from light and specific temperature ranges, and mentions a pack size of 5 prefilled pens, each containing 3 mL. It includes lot and NDC numbers and advises following dosage instructions from the package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.